What new drugs mean for thyroid eye disease treatment
Broadening treatment options for thyroid eye disease
More than one in three people with Graves’ disease, an autoimmune disease that causes the thyroid to produce too much hormone, also develop thyroid eye disease (TED). For someone living with TED, the changes can touch every part of daily life.
Eyelids that used to close all the way at night now leave a strip of the eye exposed, so mornings start dry and irritated. The eyelids pull back, making the eyes appear more prominent and often giving them a wide, startled look that may make some people self-conscious. Reading a screen for more than a few minutes can cause eye strain, and turning quickly to glance at something can trigger double vision. Many people with TED endure symptoms that flare, ease and flare again, with little warning. Left unaddressed, the disease can also threaten eyesight, although serious visual impairment is uncommon.
Until 2020, people with TED had two main treatment options. They could be prescribed steroids to calm inflammation and surgery to address the eyes’ physical changes. Neither directly treated the condition itself. Teprotumumab-trbw changed that in 2020, becoming the first U.S. Food and Drug Administration (FDA)-approved drug for the condition. In June 2026, a second drug, veligrotug-vvze, was approved for the treatment of active and chronic TED. In October 2026, a third drug, satralizumab-mwge, became the first TED treatment that patients can inject at home after proper training.
All three medications are FDA-approved to treat thyroid eye disease (TED), regardless of disease activity or duration. Satralizumab, however, is approved only for adults. Teprotumumab was first approved in 2020. In 2023, the FDA expanded its labeling after a clinical trial showed benefits in people with longstanding, less active TED. Veligrotug received FDA approval in 2026, supported by clinical trials involving people with both active and chronic TED.
What is thyroid eye disease?
Thyroid eye disease is an autoimmune condition that affects the tissues around the eyes. It can cause the eyelids to swell and pull back, making the eyes appear to bulge forward. Symptoms can include gritty, dry and painful eyes, as well as light sensitivity and headaches. Eye movement can become difficult, and looking to the side can cause double vision.
It often appears at the same time as hyperthyroidism (overactive thyroid) or within a few months of it. However, symptoms may also begin years before or after hyperthyroidism develops. It can even occur in people who do not have hyperthyroidism.
You may also see it called Graves’ ophthalmopathy, Graves’ orbitopathy or thyroid-associated orbitopathy. These all describe the same condition.
The link between thyroid eye disease and Graves’ disease
Hyperthyroidism and Graves’ disease are closely related and can also be associated with thyroid eye disease, but they are not the same.
Hyperthyroidism
Hyperthyroidism means the thyroid gland makes more thyroid hormone than the body needs, speeding up how your body uses energy. It can cause symptoms, such as weight loss, feeling hot or sweaty, a fast heartbeat, tiredness, trouble sleeping and other symptoms.
Graves’ disease
Graves’ disease is an autoimmune condition that’s a common cause of hyperthyroidism. Normally, a hormone called thyroid-stimulating hormone (TSH) tells the thyroid how much hormone to make. In Graves’ disease, the immune system produces a protein that acts like TSH, causing the thyroid to overproduce and release excess thyroid hormone.
Graves’ disease can run in families, so having a close relative with Graves’ disease or another autoimmune thyroid condition may increase your risk. Thyroid eye disease does not follow a simple inheritance pattern, but genetic factors may also influence who develops it.
The same immune attack can affect the muscles and tissue around the eyes, leading to thyroid eye disease, also called Graves’ ophthalmopathy.
In the United States, Graves’ disease affects close to 1 in 100 people, and it’s the underlying cause in about 4 out of 5 cases of an overactive thyroid.
The connection
Graves’ disease and thyroid eye disease often occur together because both involve an abnormal immune response that can affect the thyroid gland and tissues around the eyes.
One protein involved is the insulin-like growth factor-1 receptor (IGF-1R), found on cells in the eye socket. It responds to a growth factor, a substance that helps regulate how cells grow and function. IGF-1R also interacts with another receptor that responds to thyroid-stimulating hormone.
In TED, abnormal immune activity involving these receptors can cause inflammation, swelling and increased fatty tissue behind the eyes. Over time, scar tissue may also develop. These changes can cause the eyes to bulge and affect how they move.
What can raise the risk of thyroid eye disease?
Not everyone with Graves’ disease develops eye problems, and researchers cannot yet predict who will. Smoking is one modifiable risk factor that stands out.
People with Graves’ disease who smoke are more likely to develop TED than those who don’t. When it does develop in someone who smokes, the condition tends to be more severe and less responsive to treatment. Quitting smoking is one of the most important steps a person with Graves’ disease can take to protect their eyes.
Other factors appear to raise risk, including thyroid levels that swing high and low rather than staying steady. Keeping your thyroid levels stable is important to protect your eyes.
How thyroid eye disease is treated
People with Graves’ disease may need medications, radioactive iodine (RAI) or thyroid surgery to possibly bring thyroid function back to normal. These options affect the eyes differently. RAI can sometimes trigger thyroid eye disease or make existing eye disease worse. The risk is higher in people who smoke and in those who already have eye involvement. When radioactive iodine is the right choice for someone at risk, doctors may give a short course of steroids along with it to protect the eyes.
But TED can change, or even worsen, in the months and years after the thyroid issues have been brought under control. That’s why TED requires separate treatment, based on how active it is and how much it affects daily life.
Treatment for mild TED focuses on protecting the eyes and easing discomfort with artificial tears, thick ointment at night or taping the eyelids closed.
For moderate to severe TED, doctors may use IV steroids to calm inflammation. Other options include immune-calming medicines or targeted drugs, such as teprotumumab, veligrotug or satralizumab. In milder cases, doctors sometimes recommend a selenium supplement for a limited period.
Teprotumumab and veligrotug both work by binding to IGF-1R and preventing it from activating. With the receptor blocked, the signal driving swelling and tissue growth slows down. Both drugs help reduce eye bulging and double vision, even though neither treats the thyroid itself.
Satralizumab works differently by blocking the effects of interleukin-6 (IL-6), a protein that helps regulate inflammation and immune activity. However, researchers do not yet fully understand how this action helps treat thyroid eye disease. For vision-threatening stages, high-dose steroids may be necessary.
Vision loss in TED is uncommon but can occur if the eyes don’t fully close, exposing the front of the eye (cornea) and causing damage. In rare cases, swollen muscles behind the eye press on the optic nerve, the nerve that connects the eye to the brain.
Contact your eye doctor the same day or go to an emergency facility if you notice:
- Sudden or significant vision changes
- Colors looking washed out, duller or grayer, especially in one eye
- Vision that seems dim, as though a light has been turned down
- Double vision that is new or getting worse quickly
- An eye that won’t close all the way, or a new sore or cloudy patch on the surface of the eye
- Severe or increasing pain behind the eye
Once the disease has settled and stayed stable for several months, surgery can help with bulging, double vision and eyelid position.
Veligrotug
Veligrotug is approved for thyroid eye disease, whether it is active or chronic. It was tested against a placebo (a treatment with no active medicine) in two trials, one in people with active disease and one in people with chronic disease. In both trials, more participants on veligrotug had a meaningful reduction in eye bulging after at 15 weeks compared to people on placebo. Double vision also improved more often with veligrotug than with a placebo.
This drug is given as an infusion once every three weeks, based on body weight, for a total of five infusions over about 12 weeks. It’s given on its own, not combined with other medicines. The first infusion takes about 45 minutes. Depending upon the person’s tolerance, subsequent infusions may last anywhere from 30 to 45 minutes.
Teprotumumab
Teprotumumab can be used at any stage of the disease, regardless of how long it has been present. It was tested against a placebo in two studies for people with active thyroid eye disease. More participants on teprotumumab had a reduction in eye bulging than those on placebo. Among participants with double vision at the start of the trial, more improved with teprotumumab than with placebo.
This drug is given as an infusion once every three weeks, based on body weight, for a total of eight infusions. It’s given on its own, not combined with other medicines. The first two infusions take at least 90 minutes each. Later infusions can be shortened to 60 minutes if they’re well tolerated or stay at 90 minutes if they aren’t.
Both drugs are given in an infusion center, a hospital outpatient unit, or in some cases, at home through a home-infusion service.
Satralizumab
Satralizumab is approved for adults with thyroid eye disease, whether the condition is active or has been present for a long time. In one clinical trial, people receiving satralizumab were more likely than those receiving a placebo to have reduced eye bulging and improved double vision after 24 weeks. A second trial found a smaller difference in eye bulging.
Unlike the other two medications, satralizumab is injected rather than given through an IV. The dose depends on the person's body weight. The first three injections are given two weeks apart, followed by one injection every four weeks. With proper training and their doctor's approval, patients or caregivers may give the injections at home.
What are the possible side effects?
Like other prescription medications, TED treatments can cause side effects, although not everyone experiences them. Some risks are more serious than others and may require testing or monitoring before and during treatment.
Teprotumumab and veligrotug
Teprotumumab and veligrotug have similar safety warnings. Your doctor will explain which symptoms to watch for and when to seek medical attention.
These drugs can cause a reaction during or shortly after an infusion. They may also cause serious hearing problems, including hearing loss that might not go away. They may worsen inflammatory bowel disease (IBD), and cases have been reported in people without a previous diagnosis. They may also raise blood sugar, so people with diabetes should discuss whether changes to their treatment or monitoring are needed.
Encephalopathy, a condition that affects brain function, has also been reported in people receiving teprotumumab. Symptoms can include confusion, memory problems and unusual changes in behavior. Seek immediate medical attention if these symptoms occur during treatment.
Satralizumab
Satralizumab has different safety risks. It can make infections more likely, including some that can be serious. It may also affect the liver, reduce certain white blood cells that help fight infection or cause allergic reactions.
Before treatment, doctors test for hepatitis B and tuberculosis and check for signs of liver problems. Regular blood tests are also needed during treatment to monitor liver health and white blood cell levels.
Unlike the other two drugs, satralizumab does not have a specific FDA warning about hearing problems.
TED drugs and pregnancy
Teprotumumab and veligrotug may harm an unborn baby. Women who could become pregnant should use effective birth control before starting either medication, throughout treatment and for six months after the last dose. For satralizumab, there is not enough information to know how it might affect a developing baby.
How do the TED medications differ?
Teprotumumab and veligrotug both act on the same pathway. However, the two drugs differ in how long they’ve been available and how they’re dosed. Veligrotug became available in 2026 and requires five infusions over about 12 weeks. Teprotumumab became available in 2020 and requires eight infusions over about five months.
Satralizumab works differently from the other medications and is given as an injection rather than through an IV. After the first three doses, injections are given every four weeks and may be administered at home after proper training. Regular follow-up appointments and blood tests are still needed to monitor for side effects.
No clinical trial has directly compared the three medications. Each was studied separately in different groups of people, making it difficult to determine how their effectiveness compares. Differences in treatment length or how a medication is given may make one option more convenient, but they do not necessarily mean it works better than another.
Talk to your doctor
If you’ve been diagnosed with thyroid eye disease, talk with your doctor about the treatment that’s right for you. Because the disease can range from mild irritation to more serious swelling that threatens your vision, some people do well with medicine alone, while others require additional treatment.
Doctors will weigh how active and severe the disease is, how much it’s affecting your daily life and how you’ve responded to earlier therapies. Your care team will also consider your overall health, your eye health and how well your thyroid levels are controlled to determine the ideal approach for you.







